GSK, the UK’s second-biggest drugmaker, has unveiled a $2.2bn (£1.6bn) deal to amass a Californian biotech firm which is creating a drug that goals to guard in opposition to extreme meals allergy symptoms akin to nuts, milk and eggs.
Support Greater and Subscribe to view content
This is premium stuff. Subscribe to read the entire article.
Login if you have purchased
